438 related articles for article (PubMed ID: 29691773)
21. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
[TBL] [Abstract][Full Text] [Related]
22. Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ren S; Squires H; Hock E; Kaltenthaler E; Rawdin A; Alifrangis C
Pharmacoeconomics; 2019 Sep; 37(9):1073-1080. PubMed ID: 30547369
[TBL] [Abstract][Full Text] [Related]
23. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Hoyle MW; Snowsill TM; Cooper C; Varley-Campbell JL; Rudin CE; Mujica Mota RE
Pharmacoeconomics; 2017 Mar; 35(3):363-373. PubMed ID: 27752999
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
26. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
27. Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Stevenson M; Archer R; Stevens JW; Goka E; Clowes M; Scott DL; Young A
Pharmacoeconomics; 2017 Nov; 35(11):1141-1151. PubMed ID: 28550592
[TBL] [Abstract][Full Text] [Related]
28. Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Claxton L; O'Connor J; Woolacott N; Wright K; Hodgson R
Pharmacoeconomics; 2019 May; 37(5):645-654. PubMed ID: 30298279
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib for Treating Waldenström's Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens J; Simpson E; Thokala P; Wong R; Wright J; Auer R
Pharmacoeconomics; 2019 Jan; 37(1):7-18. PubMed ID: 29951793
[TBL] [Abstract][Full Text] [Related]
30. Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pouwels XGLV; Petersohn S; Carrera VH; Denniston AK; Chalker A; Raatz H; Armstrong N; Shah D; Witlox W; Worthy G; Noake C; Riemsma R; Kleijnen J; Joore MA
Pharmacoeconomics; 2020 May; 38(5):431-441. PubMed ID: 31701471
[TBL] [Abstract][Full Text] [Related]
31. Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Whyte S; Gomersall T; Ren S; Wong R; Chambers D; Tappenden P
Pharmacoeconomics; 2017 Jul; 35(7):717-726. PubMed ID: 27943135
[TBL] [Abstract][Full Text] [Related]
32. Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Carroll C; Tappenden P; Rafia R; Hamilton J; Chambers D; Clowes M; Durrington P; Qureshi N; Wierzbicki AS
Pharmacoeconomics; 2017 May; 35(5):537-547. PubMed ID: 28285379
[TBL] [Abstract][Full Text] [Related]
33. The Clinical and Cost Effectiveness of Inotuzumab Ozogamicin for the Treatment of Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal.
Cox E; Wade R; Peron M; Dietz KC; Eastwood A; Palmer S; Griffin S
Pharmacoeconomics; 2019 Sep; 37(9):1081-1091. PubMed ID: 30887470
[TBL] [Abstract][Full Text] [Related]
34. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
35. Ustekinumab for Treating Moderately to Severely Active Crohn's Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Hodgson R; Walton M; Biswas M; Mebrahtu T; Woolacott N
Pharmacoeconomics; 2018 Apr; 36(4):387-398. PubMed ID: 29192397
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
37. Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Walton M; Sharif S; Simmonds M; Claxton L; Hodgson R
Pharmacoeconomics; 2019 Oct; 37(10):1209-1217. PubMed ID: 30982165
[TBL] [Abstract][Full Text] [Related]
38. Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Cooper K; Frampton G; Harris P; Rose M; Chorozoglou M; Pickett K
Pharmacoeconomics; 2018 May; 36(5):545-553. PubMed ID: 29582406
[TBL] [Abstract][Full Text] [Related]
39. Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC; de Groot S; Fayter D; Wolff R; Armstrong N; Stirk L; Worthy G; Albuquerque de Almeida F; Kleijnen J; Al MJ
Pharmacoeconomics; 2018 Feb; 36(2):145-159. PubMed ID: 29086363
[TBL] [Abstract][Full Text] [Related]
40. Rivaroxaban for Preventing Atherothrombotic Events in People with Acute Coronary Syndrome and Elevated Cardiac Biomarkers: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pandor A; Pollard D; Chico T; Henderson R; Stevenson M
Pharmacoeconomics; 2016 May; 34(5):463-77. PubMed ID: 26689783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]